Literature DB >> 3775869

The use of rifampicin and isoniazid entrapped in liposomes for the treatment of Murine tuberculosis.

L C Orozco, F O Quintana, R M Beltrán, I de Moreno, M Wasserman, G Rodriguez.   

Abstract

Liposomes loaded with rifampicin and isoniazid were used experimentally to treat mice with severe tuberculosis. The animals were distributed in four groups. The control group and the group treated with unloaded liposomes showed the severest disease. Both groups showed the lowest accumulated survival, about 50% after 30 days. The numbers of colony-forming-units (CFU) and root specific lung weight (RSLW) were the highest and the histopathology of the lung showed marked diffuse lesions. However, the group treated with unloaded liposomes showed significantly higher growth of M. tuberculosis compared with the control. The group treated with drug and drug loaded liposomes showed a higher survival, about 85% after 30 days, and the lowest values of CFU and RSLW. The lung histology revealed considerably less inflammation which was focal. The parameters evaluated indicated a significantly better response in the group of animals treated with rifampicin and isoniazid entrapped in liposomes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3775869     DOI: 10.1016/0041-3879(86)90002-4

Source DB:  PubMed          Journal:  Tubercle        ISSN: 0041-3879


  12 in total

1.  Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid.

Authors:  D C Quenelle; G A Winchester; J K Staas; E L Barrow; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Efficacy of microencapsulated rifampin in Mycobacterium tuberculosis-infected mice.

Authors:  D C Quenelle; J K Staas; G A Winchester; E L Barrow; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice.

Authors:  P Deol; G K Khuller; K Joshi
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

4.  Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model.

Authors:  S Suarez; P O'Hara; M Kazantseva; C E Newcomer; R Hopfer; D N McMurray; A J Hickey
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

5.  Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-M. intracellulare complex infection in beige mice.

Authors:  N Düzgüneş; V K Perumal; L Kesavalu; J A Goldstein; R J Debs; P R Gangadharam
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

6.  Protective immunity to experimental tuberculosis by mannophosphoinositides of mycobacteria.

Authors:  P K Mehta; G K Khuller
Journal:  Med Microbiol Immunol       Date:  1988       Impact factor: 3.402

7.  Liposome-encapsulated-amikacin therapy of Mycobacterium avium complex infection in beige mice.

Authors:  M H Cynamon; C E Swenson; G S Palmer; R S Ginsberg
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

8.  Pharmacokinetics and in vivo activity of liposome-encapsulated gentamicin.

Authors:  C E Swenson; K A Stewart; J L Hammett; W E Fitzsimmons; R S Ginsberg
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

9.  Tuftsin-bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice.

Authors:  A Agarwal; H Kandpal; H P Gupta; N B Singh; C M Gupta
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

10.  Liposome-encapsulated ampicillin against Listeria monocytogenes in vivo and in vitro.

Authors:  I A Bakker-Woudenberg; A F Lokerse; J C Vink-van den Berg; F H Roerdink
Journal:  Infection       Date:  1988       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.